NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

NDA FilingPrimeCPositive

AI Analysis

Summary

NeuroSense has secured a Nasdaq hearing date and is targeting a New Drug Submission to Health Canada for PrimeC in December 2026, with a Phase 3 PARAGON trial progressing toward non-dilutive funding decision expected in Q1 2027.

Clinical Trial Data

Phase

Phase 3

Outcome Details

New Drug Submission to Health Canada targeted for December 2026

Importance:6/10

Sentiment:

0.50

regulatoryNDA filingPhase 3 trialPARAGON trialfundingNasdaqHealth Canada

Related Companies

$NRSNW

Read the original article

Published by PR Newswire Biotech on October 13, 2026 12:30 PM

Read Original